Showing results (31-40 of 80) with videos related to

Sort By:
Pageof 8
Frontiers in Physiology|September 12, 2022
A Wars2 mutant mouse shows a sex and diet specific change in fat distribution, reduced food intake and depot-specific upregulation of WAT browningMilan Mušo, Liz Bentley, Lucie Vizor, et al.
Medical Image Computing and Computer-Assisted Intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention|June 24, 2014
Amygdala Atrophy in MCI/Alzheimer's Disease in the BIOCARD cohort based on Diffeomorphic MorphometryMichael I Miller, Laurent Younes, J Tilak Ratnanather, et al.
Clinical Pharmacokinetics|June 23, 2025
Population Pharmacokinetics and Exposure-Response Analysis of Benralizumab in Chinese Adults, Adolescents, and Pediatric Participants with Severe Eosinophilic AsthmaYuwen Jin, Benjamin Guiastrennec, Miriam Stuke, et al.
Allergy, Asthma & Immunology Research|June 8, 2019
Efficacy and Safety of Benralizumab for Korean Patients With Severe, Uncontrolled Eosinophilic AsthmaHae Sim Park, Sang Haak Lee, Sook Young Lee, et al.
The New England Journal of Medicine|May 23, 2017
Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe AsthmaParameswaran Nair, Sally Wenzel, Klaus F Rabe, et al.
Clinical Endocrinology|February 22, 2023
Association of GDF15 levels with body mass index and endocrine status in β-thalassaemiaYanislava Karusheva, Clive J Petry, Nirmani Yasara, et al.
Advances in Therapy|March 14, 2022
Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with BenralizumabAndrew Menzies-Gow, Flavia L Hoyte, David B Price, et al.
The Lancet. Respiratory Medicine|November 13, 2018
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trialWilliam W Busse, Eugene R Bleecker, J Mark FitzGerald, et al.
The Journal of Allergy and Clinical Immunology|February 20, 2021
Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatmentWilliam W Busse, Eugene R Bleecker, J Mark FitzGerald, et al.
Endocrinology, Diabetes & Metabolism Case Reports|December 23, 2015
Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptidesBenjamin G Challis, Nicolai J Wewer Albrechtsen, Vishakha Bansiya, et al.
Pageof 8